Cat. No.: HY-N0196

Copy Link Print Information

Baicalein

(Synonyms: 5,6,7-Trihydroxyflavone)

38 Cited Publications

Customer Review

Based on 38 publication(s) in Google Scholar

Baicalein (5,6,7-Trihydroxyflavone) is a xanthine oxidase inhibitor with an IC₅₀ value of 3.12 μM.

For research use only. We do not sell to patients.

Purity: 98.51%
CAS No.: 491-67-8
Formula: C₁₅H₁₀O₅
Molecular Weight:270.24

Storage:

4°C, protect from light

* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

Baicalein Chemical Structure

CAS No.: 491-67-8

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (38)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

Baicalein (5,6,7-Trihydroxyflavone) is a xanthine oxidase inhibitor with an IC₅₀ value of 3.12 μM.

IC₅₀ & Target

IC50: 3.12 μM (xanthine oxidase)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
3T3-L1	IC₅₀	29.81 μM Compound: Baicalein	Cytotoxicity against mouse 3T3L1 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay Cytotoxicity against mouse 3T3L1 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay	[PMID: 28818460]
A549	IC₅₀	13 μM Compound: 1, Baicalein	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 24507925]
BALB/3T3	IC₅₀	342.3 μM Compound: 3	Growth inhibition of BALB/c mouse cloned 3T3/A31 cells after 72 hrs by nigrosin assay Growth inhibition of BALB/c mouse cloned 3T3/A31 cells after 72 hrs by nigrosin assay	[PMID: 10096863]
BJ	EC₅₀	>86.2069 μM Compound: 3	Antiproliferative activity against human BJ cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human BJ cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]
C8166	CC₅₀	30.3 μg/mL Compound: 2	Cytotoxicity against human C8166 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human C8166 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 24794743]
C8166	EC₅₀	1.67 μg/mL Compound: 2	Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity by measuring syncytial cell number after 3 days by inverted microscopic analysis Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity by measuring syncytial cell number after 3 days by inverted microscopic analysis	[PMID: 24794743]
Caco-2	IC₅₀	2.6 x 10^-4 M Compound: 2	Inhibition of rat intestinal sucrase expressed in human Caco-2 cells Inhibition of rat intestinal sucrase expressed in human Caco-2 cells	[PMID: 9834167]
Caco-2	IC₅₀	3.5 x 10^-5 M Compound: 2	Inhibition of human intestinal sucrase in human Caco-2 cell membrane Inhibition of human intestinal sucrase in human Caco-2 cell membrane	[PMID: 9834167]
Calu-3	CC₅₀	91 μM Compound: 1	Cytotoxicity against human Calu-3 cells assessed as inhibition of cell growth incubated for 4 days by MTS assay Cytotoxicity against human Calu-3 cells assessed as inhibition of cell growth incubated for 4 days by MTS assay	[PMID: 36965227]
Calu-3	CC₅₀	9.1 μM Compound: Baicalein	Cytotoxicity against human Calu-3 cells incubated for 4 days by MTS assay Cytotoxicity against human Calu-3 cells incubated for 4 days by MTS assay	[PMID: 37437351]
CHO	IC₅₀	>350 μM Compound: 1	Displacement of [3H]LSD from human 5HT7 receptor expressed in CHO cells Displacement of [3H]LSD from human 5HT7 receptor expressed in CHO cells	[PMID: 12713409]
DLD-1	IC₅₀	>20 μM Compound: 1; Baicalein	Antiproliferative activity against human DLD1 cells after 24 hrs by MTT assay Antiproliferative activity against human DLD1 cells after 24 hrs by MTT assay	10.1039/C5MD00163C
DLD-1	IC₅₀	>20 μM Compound: 1; Baicalein	Antiproliferative activity against human DLD1 cells after 72 hrs by MTT assay Antiproliferative activity against human DLD1 cells after 72 hrs by MTT assay	10.1039/C5MD00163C
DLD-1	IC₅₀	27.88 μM Compound: 1; Baicalein	Antiproliferative activity against human DLD1 cells after 48 hrs by MTT assay Antiproliferative activity against human DLD1 cells after 48 hrs by MTT assay	10.1039/C5MD00163C
HEK293	IC₅₀	4.4 μM Compound: Baicalein	Inhibition of human recombinant UGT1A1 expressed in HEK293 cells assessed as reduction in estradiol 3-glucuronidation by LC-MS/MS method Inhibition of human recombinant UGT1A1 expressed in HEK293 cells assessed as reduction in estradiol 3-glucuronidation by LC-MS/MS method	[PMID: 21030469]
HEK293	IC₅₀	7 μM Compound: Baicalein	Inhibition of human recombinant UGT1A1 expressed in HEK293 cells assessed as reduction in bilirubin glucuronidation by LC-MS/MS method Inhibition of human recombinant UGT1A1 expressed in HEK293 cells assessed as reduction in bilirubin glucuronidation by LC-MS/MS method	[PMID: 21030469]
HEK-293T	CC₅₀	<=200 μM Compound: Baicalein	Cytotoxicity against HEK293T cells expressing human ACE2 assessed as reduction in cell viability incubated for 4 hrs by MTT assay Cytotoxicity against HEK293T cells expressing human ACE2 assessed as reduction in cell viability incubated for 4 hrs by MTT assay	[PMID: 37437351]
HepG2	IC₅₀	28.3 μM Compound: 1, Baicalein	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 24507925]
HepG2	EC₅₀	60 μM Compound: 3	Antiproliferative activity against human HepG2 cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human HepG2 cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]
HepG2	IC₅₀	28.09 μM Compound: 1; Baicalein	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	10.1039/C5MD00163C
HT-29	EC₅₀	10.3 μM Compound: Baicalein	Agonist activity at GPR35 receptor in human HT-29 cells after 10 mins by dynamic mass redistribution assay Agonist activity at GPR35 receptor in human HT-29 cells after 10 mins by dynamic mass redistribution assay	[PMID: 24900447]
HT-29	IC₅₀	28.2 μM Compound: Baicalein	Desensitization of GPR35 receptor in human HT-29 cells assessed as inhibition of zaprinast-induced dynamic mass redistribution after 10 mins Desensitization of GPR35 receptor in human HT-29 cells assessed as inhibition of zaprinast-induced dynamic mass redistribution after 10 mins	[PMID: 24900447]
HT-29	IC₅₀	>20 μM Compound: 1; Baicalein	Antiproliferative activity against human HT-29 cells after 24 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 24 hrs by MTT assay	10.1039/C5MD00163C
HT-29	IC₅₀	18.05 μM Compound: 1; Baicalein	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	10.1039/C5MD00163C
HT-29	IC₅₀	18.36 μM Compound: 1; Baicalein	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	10.1039/C5MD00163C
Huh-7	CC₅₀	>50 μM Compound: 16	Cytotoxicity against human Huh7.5.1 cells by MTT assay Cytotoxicity against human Huh7.5.1 cells by MTT assay	[PMID: 22445328]
Huh-7	EC₅₀	33.9 μM Compound: 16	Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay	[PMID: 22445328]
Huh-7	CC₅₀	>100 μM Compound: BE	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 35738350]
Huh-7	CC₅₀	>100 μM Compound: Baicalein	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability by CCK8 assay relative to control Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability by CCK8 assay relative to control	[PMID: 36804408]
HUVEC	IC₅₀	3.7 μM Compound: 1	Inhibition of trypsin-induced elevation in PAI1 production in HUVEC by ELISA Inhibition of trypsin-induced elevation in PAI1 production in HUVEC by ELISA	[PMID: 9214730]
KB	IC₅₀	62.3 μM Compound: 1	Inhibitory activity against KB cell line after 72 h of drug exposure Inhibitory activity against KB cell line after 72 h of drug exposure	[PMID: 15481991]
KB	IC₅₀	62.3 μM Compound: S1	Cytotoxicity against human KB cells after 3 days Cytotoxicity against human KB cells after 3 days	[PMID: 18722769]
KB	IC₅₀	87.1 μM Compound: S1	Cytotoxicity against multi-drug resistant human KB cells overexpressing mdr1 after 3 days Cytotoxicity against multi-drug resistant human KB cells overexpressing mdr1 after 3 days	[PMID: 18722769]
KB 3-1	EC₅₀	41 μM Compound: 1	Concentration that causes 50% of maximum vinblastine accumulation in KB/MDR cells in 1 h Concentration that causes 50% of maximum vinblastine accumulation in KB/MDR cells in 1 h	[PMID: 15481991]
KB 3-1	IC₅₀	87.1 μM Compound: 1	Inhibitory activity against KB/MDR cell line after 72 hr of drug exposure Inhibitory activity against KB/MDR cell line after 72 hr of drug exposure	[PMID: 15481991]
KOPN-8	EC₅₀	16 μM Compound: 3	Antiproliferative activity against human KOPN8 cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human KOPN8 cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]
MCF7	GI₅₀	32.8 μM Compound: 1	Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 21496973]
MCF7	IC₅₀	5.3 μg/mL Compound: Baicalein	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 3 days by beta scintillation counting based [3H]-thymidine incorporation assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 3 days by beta scintillation counting based [3H]-thymidine incorporation assay	[PMID: 33257172]
NCI-H460	GI₅₀	26.7 μM Compound: 1	Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay	[PMID: 21496973]
RAW264.7	IC₅₀	13.01 μM Compound: Baicalein	Antiosteoporotic activity in mouse RAW264.7 cells assessed as inhibition of RANKL-stimulated osteoclastogenesis by TRAP assay Antiosteoporotic activity in mouse RAW264.7 cells assessed as inhibition of RANKL-stimulated osteoclastogenesis by TRAP assay	[PMID: 19339083]
RAW264.7	IC₅₀	>100 μM Compound: 2	Cytotoxicity against mouse RAW264.7 cells Cytotoxicity against mouse RAW264.7 cells	[PMID: 22101131]
RAW264.7	IC₅₀	30.4 μM Compound: 7	Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as reduction in NO production Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as reduction in NO production	[PMID: 37778427]
RBL-2H3	IC₅₀	179 μM Compound: 2	Antihistaminic activity in rat RBL2H3 cells assessed as inhibition of DNP-BSA-induced beta-hexosaminidase release preincubated for 10 mins before DNP-BSA challenge Antihistaminic activity in rat RBL2H3 cells assessed as inhibition of DNP-BSA-induced beta-hexosaminidase release preincubated for 10 mins before DNP-BSA challenge	[PMID: 14510616]
SUP-B15	EC₅₀	103 μM Compound: 3	Antiproliferative activity against human SUP-B15 cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human SUP-B15 cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]
SW480	IC₅₀	11.55 μM Compound: 1; Baicalein	Antiproliferative activity against human SW480 cells after 72 hrs by MTT assay Antiproliferative activity against human SW480 cells after 72 hrs by MTT assay	10.1039/C5MD00163C
SW480	IC₅₀	14.05 μM Compound: 1; Baicalein	Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay	10.1039/C5MD00163C
SW480	IC₅₀	16.95 μM Compound: 1; Baicalein	Antiproliferative activity against human SW480 cells after 24 hrs by MTT assay Antiproliferative activity against human SW480 cells after 24 hrs by MTT assay	10.1039/C5MD00163C
U2OS	EC₅₀	22.7 μM Compound: Baicalein	Agonist activity at GPR35 receptor in human U2OS cells coexpressing Gal4-VP16-TEV assessed as beta arrestin translocation after 5 hrs by beta lactamase reporter gene assay Agonist activity at GPR35 receptor in human U2OS cells coexpressing Gal4-VP16-TEV assessed as beta arrestin translocation after 5 hrs by beta lactamase reporter gene assay	[PMID: 24900447]
Vero	IC₅₀	6.46 μg/mL Compound: baicalein	Antiviral activity against dengue virus 2 infected in african green monkey Vero cells assessed as reduction in viral replication dosed after adsorption with 200 FFU of virus for 1 hour by foci forming unit reduction assay Antiviral activity against dengue virus 2 infected in african green monkey Vero cells assessed as reduction in viral replication dosed after adsorption with 200 FFU of virus for 1 hour by foci forming unit reduction assay	[PMID: 25564380]
Vero	CC₅₀	>200 μM Compound: Baicalein	Cytotoxicity against African green monkey Vero cells Cytotoxicity against African green monkey Vero cells	[PMID: 37437351]
Vero	CC₅₀	>500 μM Compound: Baicalein	Cytotoxicity against African green monkey Vero cells by CCK8 assay Cytotoxicity against African green monkey Vero cells by CCK8 assay	[PMID: 37437351]
Vero	CC₅₀	8.6 μM Compound: Baicalein	Cytotoxicity against African green monkey Vero cells incubated for 4 days by MTS assay Cytotoxicity against African green monkey Vero cells incubated for 4 days by MTS assay	[PMID: 37437351]
Vero C1008	CC₅₀	>200 μM Compound: Baicalein	Cytotoxicity against African green monkey Vero E6 cells incubated for 3 hrs by CCK-8 assay Cytotoxicity against African green monkey Vero E6 cells incubated for 3 hrs by CCK-8 assay	[PMID: 33186044]
Vero C1008	CC₅₀	>200 μM Compound: 211	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability by CellTiterGlo assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability by CellTiterGlo assay	[PMID: 34798775]
Vero C1008	CC₅₀	8.6 μM Compound: 1	Cytotoxicity against african green monkey Vero E6 cells assessed as inhibition of cell growth incubated for 4 days by MTS assay Cytotoxicity against african green monkey Vero E6 cells assessed as inhibition of cell growth incubated for 4 days by MTS assay	[PMID: 36965227]
Vero C1008	CC₅₀	>200 μM Compound: 1	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability by CCK8 assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability by CCK8 assay	[PMID: 37257024]
Vero C1008	CC₅₀	>50 μM Compound: 14	Cytotoxicity against african green monkey Vero E6 cells by CCK-8 assay Cytotoxicity against african green monkey Vero E6 cells by CCK-8 assay	[PMID: 37257212]
Vero C1008	CC₅₀	>200 μM Compound: 86	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell growth incubated for 24 hrs by WST-8 assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell growth incubated for 24 hrs by WST-8 assay	[PMID: 37597436]
ZR-75-1	EC₅₀	25 μM Compound: 1, Baicalein	Increase in intracellular Ca2+ level in human ZR-75-1 cells treated for 25 secs by fura-2-AM dye-based spectrofluorophotometric analysis in presence of Ca2+ containing medium Increase in intracellular Ca2+ level in human ZR-75-1 cells treated for 25 secs by fura-2-AM dye-based spectrofluorophotometric analysis in presence of Ca2+ containing medium	[PMID: 26154615]
ZR-75-1	EC₅₀	35 μM Compound: 1, Baicalein	Increase in intracellular Ca2+ level in human ZR-75-1 cells treated for 25 secs by fura-2-AM dye-based spectrofluorophotometric analysis in presence of Ca2+-free medium Increase in intracellular Ca2+ level in human ZR-75-1 cells treated for 25 secs by fura-2-AM dye-based spectrofluorophotometric analysis in presence of Ca2+-free medium	[PMID: 26154615]

In Vitro

Baicalein suppresses mitogen induced T cell proliferation and cytokine secretion in vitro. Pre-treatment with baicalein significantly suppresses Con A or anti-CD3/CD28 mAb induced proliferation as well as cytokine secretion at 25 μM. Baicalein treatment induces DNA binding of NF-κB but inhibits thioredoxin activity in the nuclear compartment^[2]. Baicalein suppresses proliferation, migration, and invasion of MDA-MB-231 cells in a time- and dose-dependent manner. Baicalein significantly decreases the expression of SATB1 in MDA-MB-231 cells. Baicalein also downregulates the expression of Wnt1 and β-catenin proteins and transcription level of Wnt/β-catenin-targeted genes^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Baicalein suppresses induction of graft versus host disease but does not inhibit homeostatic proliferation of T-cells in mice. This observation clearly shows potent anti-inflammatory activity of baicalein in vivo^[2]. Rats treated with baicalein are protected against an increase in heart to body weight ratio, plasma level of brain natriuretic peptides, intraventricular septum thickness, myocardial collagen volume of left ventricle (all P<0.05, respectively). The antifibrotic effects of baicalein are further illustrated by the suppressed expression of left ventricle pro-collagens I and III accompanied by the decreased expression of 12-lipoxygenase, and by reduced expression and activity of matrix metallopeptidase 9 and extracellular signal-regulated kinases. Baicalein can inhibit cardiac fibrosis in hypertensive rats^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 491-67-8
Appearance Solid
Molecular Weight 270.24
Formula C₁₅H₁₀O₅
Color Light yellow to brown
SMILES

O=C1C=C(C2=CC=CC=C2)OC3=CC(O)=C(O)C(O)=C13
Synonyms

5,6,7-Trihydroxyflavone
Structure Classification
- Flavonoids
- Flavones
- Phenols
- Polyphenols
Initial Source
- Plants
- Labiatae
- Endogenous metabolite
- Human Gut Microbiota Metabolites
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

Publications (38)

All Bio/Physico-chemical AssayCell Proliferation/Viability AssayFlow CytometryIn Vivo Efficacy StudyHistological Imaging/Staining

Sort by:

Journal Impact Factor

Theranostics

Microenvironment Activatable Nanoprodrug Based on Gripper-like Cyclic Phenylboronic Acid to Precisely and Effectively Alleviate Drug-induced Hepatitis. [Abstract]

2021 Jul 13;11(17):8301-8321. PMID: 34373743

Baicalein purchased from MedChemExpress. Usage Cited in: Theranostics. 2021 Jul 13;11(17):8301-8321. [Abstract]

Fluorescence quenching of cPBA after an interaction with various concentrations (0, 3, 6, 12, 24 μg/mL) of BE was observed.
Biosens Bioelectron

Engineering a NanoBiT biosensor for detecting angiotensin-converting enzyme-2 (hACE2) interaction with SARS-CoV-2 spike protein and screening the inhibitors to block hACE2 and spike interaction. [Abstract]

2024 Aug 3:263:116630. PMID: 39102773
Pharmacol Res

PXR triggers YAP-TEAD binding and Sirt2-driven YAP deacetylation and polyubiquitination to promote liver enlargement and regeneration in mice. [Abstract]

2023 Feb:188:106666. PMID: 36657504

Baicalein purchased from MedChemExpress. Usage Cited in: Pharmacol Res. 2023 Feb:188:106666. [Abstract]

Intracellular drug release of 80 μg/mL cPBA-BE in HepaRG cells injured by 3 mg/mL APAP (8 h) was observed.

Baicalein purchased from MedChemExpress. Usage Cited in: Pharmacol Res. 2023 Feb:188:106666. [Abstract]

Representative flow cytometry curves and quantitative data illustrating time-dependent internalization of 10 mg/mL Cy5-labeled cPBA-BE in HepaRG cells until 24 h.

Baicalein purchased from MedChemExpress. Usage Cited in: Pharmacol Res. 2023 Feb:188:106666. [Abstract]

After mice were injured by 200 mg/kg APAP for 6 h, a single intravenous injection of 100 μL 20 mg/mL cPBA-BE in PBS or 5.1 mg/mL BE in 5% DMSO (equal to 20 mg/mL cPBA-BE) was administered. The expression levels of representative factors of inflammation and oxidative stress in the liver were measured. After 18 h of treatment, homogenates of the hepatic tissues were prepared, and the concentrations of GSH, H2O2, MDA, and MPO were separately measured.

Baicalein purchased from MedChemExpress. Usage Cited in: Pharmacol Res. 2023 Feb:188:106666. [Abstract]

After mice were injured by 200 mg/kg APAP for 6 h, a single intravenous injection of 100 μL 20 mg/mL cPBA-BE in PBS or 5.1 mg/mL BE in 5% DMSO (equal to 20 mg/mL cPBA-BE) was performed. Masson trichrome (MT) staining of liver sections.
Cell Death Dis

A novel taxane SB-T-101141 triggers a noncanonical ferroptosis to overcome Paclitaxel resistance of breast cancer via iron homeostasis-related KHSRP. [Abstract]

2025 May 19;16(1):403. PMID: 40389408
Acta Pharmacol Sin

Baicalein triggers ferroptosis in colorectal cancer cells via blocking the JAK2/STAT3/GPX4 axis. [Abstract]

2024 Aug;45(8):1715-1726. PMID: 38684798
Acta Pharmacol Sin

Baicalein ameliorates ulcerative colitis by improving intestinal epithelial barrier via AhR/IL-22 pathway in ILC3s. [Abstract]

2022 Jun;43(6):1495-1507. PMID: 34671110
Phytomedicine

Functional calibration of PPARγ by baicalein reverses bone-lipid imbalance in type 2 diabetic osteoporosis. [Abstract]

2026 Mar:152:157850. PMID: 41581447
Phytomedicine

Bruceantin inhibits the c-Myc/RL27A axis to suppress tumor progression in hepatocellular carcinoma. [Abstract]

2025 Dec 24:150:157740. PMID: 41477978
Phytomedicine

Baicalein Induces Hepatic Stellate Cell Senescence and Attenuates Liver Fibrosis via CEBPZ/p53/HK2-Mediated Glycolysis Inhibition. [Abstract]

2025 Sep 3:148:157222. PMID: 41075517
Phytomedicine

Mechanistic insights into baicalein's anti-inflammatory effects in COPD: Targeting oxidative stress and CD8⁺ T cell cytotoxicity. [Abstract]

2025 Aug 19:147:157183. PMID: 40865348
Phytomedicine

Baicalein inhibits hepatitis B virus through the coiled coil domain containing protein 88A (CCDC88A)-dependent autophagy pathway. [Abstract]

2025 May:140:156577. PMID: 40023973
Int J Nanomedicine

Construction of Baicalein-Loaded Chitosan Nanoparticles for Staphylococcus aureus-Induced Lung Infection Remission. [Abstract]

2025 Oct 1:20:12009-12018. PMID: 41054631
Cell Mol Life Sci

Prolyl endopeptidase is a multifunctional host factor required for FMDV infection. [Abstract]

2025 Nov 19;82(1):408. PMID: 41258568
Anal Chim Acta

An in vivo NanoBiT-based pseudoviral biosensor for real-time monitoring of SARS-CoV-2 spike/hACE2 interactions and therapeutic screening. [Abstract]

2025 Nov 22:1376:344623. PMID: 41073017
J Enzyme Inhib Med Chem

Inhibition of 12/15-LOX hyperactivation mitigates cognitive decline in a chronic cerebral hypoperfusion mouse model and in H2O2-induced HT22 cells: therapeutic effects of brozopine. [Abstract]

2025 Dec;40(1):2547259. PMID: 40841277
Int Immunopharmacol

Baicalein upregulates macrophage TREM2 expression via TrKB-CREB1 pathway to attenuate acute inflammatory injury in acute-on-chronic liver failure. [Abstract]

2024 Jul 23:139:112685. PMID: 39047449
J Inflamm Res

Computational Systems Pharmacology, Molecular Docking and Experiments Reveal the Protective Mechanism of Li-Da-Qian Mixture in the Treatment of Glomerulonephritis. [Abstract]

2021 Dec 16;14:6939-6958. PMID: 34949932
Virol Sin

Baicalein suppresses Coxsackievirus B3 replication by inhibiting caspase-1 and viral protease 2A. [Abstract]

2024 Jul 16:S1995-820X(24)00113-5. PMID: 39025463
Antiviral Res

Identification of desoxyrhapontigenin as a novel antiviral agent against congenital Zika virus infection. [Abstract]

2023 Mar:211:105542. PMID: 36646387
Process Biochem

2021 Jan 27.
Aging (Albany NY)

Baicalein ameliorates osteoporosis via AKT/FOXO1 signaling. [Abstract]

2021 Jul 1;13(13):17370-17379. PMID: 34198266
Mol Cell Biochem

Baicalein sensitizes triple negative breast cancer MDA-MB-231 cells to doxorubicin via autophagy-mediated down-regulation of CDK1. [Abstract]

2023 Jul;478(7):1519-1531. PMID: 36413334
Exp Cell Res

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]

2020 Aug 1;393(1):112054. PMID: 32376287
Toxicol Appl Pharmacol

Exploring the mechanism of baicalein on breast cancer based on network pharmacology, molecular docking and in vivo experiments. [Abstract]

2025 May:498:117297. PMID: 40081541
Chem Biol Drug Des

Baicalein, a component of banxia xiexin decoction, alleviates CPT-11-induced gastrointestinal dysfunction by inhibiting ALOX15-mediated ferroptosis. [Abstract]

2023 Dec;102(6):1568-1577. PMID: 37735740
Mol Carcinog

Baicalein promotes KDM4E to induce BICD1 and inhibit triple-negative breast cancer progression by blocking PAR1 signaling. [Abstract]

2024 Jul;63(7):1288-1302. PMID: 38607237
J Pharm Biomed Anal

Identification of new small molecule inhibitors of PD-1/PD-L1 interaction by a comprehensive ligand fishing system. [Abstract]

2025 Nov 23:270:117281. PMID: 41308584
Immunol Res

Baicalein attenuates ovalbumin-induced allergic rhinitis through the activation of nuclear receptor subfamily 4 group a member 1. [Abstract]

2025 Jan 14;73(1):32. PMID: 39808359
BMC Oral Health

Investigation of the mechanism of baicalein in the treatment of periodontitis based on network pharmacology, molecular docking and experimental validation. [Abstract]

2024 Aug 23;24(1):987. PMID: 39180042
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
PeerJ

Regulatory mechanism of Scutellaria baicalensis Georgi on bone cancer pain based on network pharmacology and experimental verification. [Abstract]

2022 Nov 17:10:e14394. PMID: 36415861
Biochem Biophys Res Commun

Effects of intracellular iron overload on cell death and identification of potent cell death inhibitors. [Abstract]

2018 Sep 3;503(1):297-303. PMID: 29890135
Biosci Biotechnol Biochem

Baicalein-ameliorated cerebral ischemia-reperfusion injury dependent on calpain 1/AIF pathway. [Abstract]

2022 Feb 24;86(3):305-312. PMID: 34935885
In Silico Pharmacol

Targeting SARS-CoV-2 main protease (3CLpro) with Paeonia-derived phytochemicals. [Abstract]

2026 Apr 17;14(2):122. PMID: 42005983
Res Sq

2025 Mar 13.
SSRN

2024 May 2.
Preprints

2024 Jan 31.
Oxid Med Cell Longev

Cepharanthine Attenuates Early Brain Injury after Subarachnoid Hemorrhage in Mice via Inhibiting 15-Lipoxygenase-1-Mediated Microglia and Endothelial Cell Ferroptosis. [Abstract]

2022 Feb 9;2022:4295208. PMID: 35186185

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (185.02 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.7004 mL

18.5021 mL

37.0041 mL

5 mM

0.7401 mL

3.7004 mL

7.4008 mL

10 mM

0.3700 mL

1.8502 mL

3.7004 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.5 mg/mL (9.25 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 2.5 mg/mL.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (9.25 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 2.5 mg/mL.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/saline water

Solubility: 20 mg/mL (74.01 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[3]

MTT assay is conducted to evaluate the effect of baicalein on proliferation of breast cancer cells. MDA-MB-231 cells are routinely digested, collected, and then seeded in 96-well plates at a density of 8×10³ cells/well. After incubation for 12-24 hours, cells are treated with 0, 20, 40, 60, 80, 100, and 120 μM baicalein according to their experimental grouping and then incubated at 37°C for 24, 48, and 72 hours^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]^[4]

Rats: Baicalein is suspended in 1% methylcellulose. Rats are treated with baicalein suspension via oral garvage. SHR and WKY rats are divided into 4 groups (n=8 per group): 12-week treatment with high-dose (200 mg/kg/day) or low-dose (50 mg/kg/day) group; and 4-week treatment with high-dose or low-dose group. The 12-week and 4-week negative control groups of SHR and WKY rats (n=8 per group) receive vehicle while positive control groups (Val group, n=8 per group) receive valsartan (20 mg/kg/day) for comparison^[4].

Mice: To study the in vivo anti-inflammatory efficacy of baicalein, graft-versus-host disease (GVHD) model is used. Splenic lymphocytes from C57BL/6 mice are incubated with baicalein in vitro (25 μM, 4h) and adoptively transferred to immune-compromised Balb/c mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Shieh DE,et al. Antioxidant and free radical scavenging effects of baicalein, baicalin and wogonin. Anticancer Res. 2000 Sep-Oct;20(5A):2861-5. [Content Brief]

[2]. Patwardhan RS, et al. Baicalein exhibits anti-inflammatory effects via inhibition of NF-κB transactivation. Biochem Pharmacol. 2016 May 15;108:75-89. [Content Brief]

[3]. Ma X, et al. Baicalein suppresses metastasis of breast cancer cells by inhibiting EMT via downregulation of SATB1 and Wnt/β-catenin pathway. Drug Des Devel Ther. 2016 Apr 18;10:1419-41. [Content Brief]

[4]. Kong EK, et al. A novel anti-fibrotic agent, baicalein, for the treatment of myocardial fibrosis in spontaneously hypertensiverats. Eur J Pharmacol. 2011 May 11;658(2-3):175-81. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.7004 mL	18.5021 mL	37.0041 mL	92.5104 mL
	5 mM	0.7401 mL	3.7004 mL	7.4008 mL	18.5021 mL
	10 mM	0.3700 mL	1.8502 mL	3.7004 mL	9.2510 mL
	15 mM	0.2467 mL	1.2335 mL	2.4669 mL	6.1674 mL
	20 mM	0.1850 mL	0.9251 mL	1.8502 mL	4.6255 mL
	25 mM	0.1480 mL	0.7401 mL	1.4802 mL	3.7004 mL
	30 mM	0.1233 mL	0.6167 mL	1.2335 mL	3.0837 mL
	40 mM	0.0925 mL	0.4626 mL	0.9251 mL	2.3128 mL
	50 mM	0.0740 mL	0.3700 mL	0.7401 mL	1.8502 mL
	60 mM	0.0617 mL	0.3084 mL	0.6167 mL	1.5418 mL
	80 mM	0.0463 mL	0.2313 mL	0.4626 mL	1.1564 mL
	100 mM	0.0370 mL	0.1850 mL	0.3700 mL	0.9251 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Baicalein

Anti-Infection Compound Library

Metabolism/Protease Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Medicine Food Homology Compound Library

Phenols Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Flavonoids Library

Gut Microbial Metabolite Library

Microbial Metabolite Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Antiviral Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

FDA-Approved Anticancer Drug Library

Anti-Aging Natural Product Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Cell Death Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Cosmetic Ingredient Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

RNA Binding Bioactive Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Baicalein

Biological Activity

Chemical Information

Publications (38)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Baicalein Related Classifications

Cat. No.: HY-N0196